| DC48395 |
ACT-1004-1239
|
ACT-1004-1239 is a potent, selective, orally available CXCR7 antagonist with an IC50 value of 3.2 nM. |
| DC10423 |
Motixafortide(BKT140)
|
Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC50 vakue of ～1 nM. |
| DC7341 |
WZ 811
|
WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM. |
| DC8851 |
VUF11207
|
VUF11207 is a highly potent CXCR7 agonist. VUF11207 induces recruitment of β-arrestin2 to the CXCR7 followed by internalization of the receptor. |
| DC7336 |
Vicriviroc maleate(Sch-417690)
|
Vicriviroc Malate is a potent CKR-5 (CCR5) antagonist with IC50 of 0.91 nM. |
| DC7913 |
SB225002
|
SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested. |
| DC9251 |
RS-102895 hydrochloride
|
RS 102895 hydrochloride is a chemokine receptor CCR2 antagonist. |
| DC9411 |
Reparixin
|
Reparixin(DF 1681Y) is an inhibitor of CXCL8 receptor, also inhibit CXCR1 and CXCR2 activation, which has been shown to attenuate inflammatory responses in various injury models. |
| DC8741 |
Plerixafor octahydrochloride
|
Plerixafor octahydrochloride(AMD3100 8HCL) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. |
| DC5055 |
Plerixafor (AMD3100)
|
Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. |
